Introduction to the United States Food and Drug Administration (FDA) and FDA Inspection Process VOICE

Similar documents
Standard Operating Procedures

16 STUDY OVERSIGHT Clinical Quality Management Plans

GCP Inspection by PMDA

Building Quality into Clinical Trials. Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies

AN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES

4.2. Clinical Trial Monitor (or Monitor): The person responsible for monitoring the data on behalf of the sponsor or contract research organization.

Unofficial copy not valid

Training components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA

The GCP Perspective on Study Monitoring

Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV)

Section 14. Study Reporting Plan

General Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility

EMA Inspection Site perspective

SARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY

3 HPTN OPERATIONAL COMPONENTS

NN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION

Regulatory Binder Checklist for FDA-Regulated Sponsor/Sponsor-Investigator Studies

Document Title: Study Data SOP (CRFs and Source Data)

36 th Annual Meeting Preconference Workshop P4 Handout

Dr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015

3 THE MICROBICIDE TRIALS NETWORK S OPERATIONAL COMPONENTS

managing or activities.

The Clinical Research Center Research Practice Manual. Guideline for Study Document and Data Handling RPG-08. Guideline. Purpose.

EMA & FDA Inspections: Site perspective. Shandukani Research Centre

Vascular Surgery Academic Coordinating Center (VSACC) & Peripheral Vascular Core Lab (PVCL)

Section 9. Study Product Considerations for Non- Pharmacy Staff

Quality Assurance and Site Monitoring Visits. Introduction. Training Outline

Quality Assurance and Regulatory Compliance Office and USAMRIID FDA Risk Management. Carolyn Mentzer Chief, QARCO

Site Closedown Checklist for UoL Sponsored CTIMP Studies

Good Clinical Practice: A Ground Level View

Conducting Monitoring Visits for Investigator-Initiated Trials (IITs)

General Administration GA STANDARD OPERATING PROCEDURE FOR Document Development and Change Control

Good Documentation Practices. Human Subject Research. for

Successful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics

Investigator-Initiated Studies: When you re the Sponsor. Cheri Robert & Tammy Mah-Fraser

STANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager

Good Clinical Practice. Lisa de Blieck MPA CCRC Clinical Trials Coordination Center

FDA SEATTLE DISTRICT REGULATORY UPDATE

Standard Operating Procedure (SOP) Research and Development Office

Regulatory Inspections

QUALITY ASSURANCE PROGRAM

21 PUBLICATIONS POLICY RESPONSIBILITIES DEFINITIONS Tier 1 Priorities Tier 2 Priorities

VCU Clinical Research Quality Assurance Assessment

Checklist prior to recruiting first patient

Audit and Inspection

ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, N.J November 28,2011

GCP INSPECTION CHECKLIST

Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026

Vertex Investigator-Initiated Studies Program Overview

QUALITY TIPS FOR CLINICAL SITES. Athena Thomas-Visel. Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES

SOP-QA-28 V2. Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head of School

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals

POINT Trial Organization

Self-Monitoring Tool

Joint R&D Support Office SOP S-2011 UHL

HIC Standard Operating Procedure. For-Cause Audits of Human Research Studies

FDA Inspection Readiness

Office of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators

Solutions for GCP Compliance Challenges. September 23, 2015 Northwestern University IRB Brown Bag Session

Solutions for GCP Compliance Challenges

Clinical Trial Readiness Checklist October 2014

Research Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review

Silom Community Update for MTN-017. Wipas Wimonsate Bangkok CRS Study Coordinator

ACTIONS/PSOP/001 Version 1.0 Page 2 of 6

11/18/2016. UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities SESSION 4

21 PUBLICATIONS POLICY RESPONSIBILITIES Timelines... 3 The SDMC will release specific timelines for each major conference...

Research Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004

Study Monitoring Plan Template

SOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup

Monitoring Clinical Trials

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Initially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009 1:51 PM Approval By student13 student13 on 11/24/2009 1:52 PM Attendees

Audits/Inspections Be Prepared for Anything

MHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager

CLIC Clinical Investigator (And Site Staff) Certification

Trial Management: Trial Master Files and Investigator Site Files

IN ACCORDANCE WITH THIS INTERNATIONAL DEVICE STANDARD

Mastering Clinical Research April 19, :30 am

COMMISSION ON LABORATORY ACCREDITATION. Laboratory Accreditation Program TEAM LEADER ASSESSMENT OF DIRECTOR & QUALITY CHECKLIST

Joint Statement on the Application of Good Clinical Practice to Training for Researchers

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network of Clinical Research Professionals

Clinical Trial Quality Assurance Common Findings

Pharmaceutical Services Report to Joint Conference Committee September 2010

HVTN Research and Mentorship Program Grants

RITAZAREM CRF Completion Guidelines

S1404: GENERAL DATA MANAGEMENT UPDATES

Documenting the Story of a Clinical Trial: Concept to CAPA. Lori T. Gilmartin Gilmartin Consulting LLC

Clinical Research Seminar

Why do we need an addendum to ICH E6?

Effective Date: April 2014 Revision: September 29, Executive Chair, Co-Chairs, NSHA REB Members, REB Office Personnel, Researchers.

Effective Date: 11/09 Policy Chronicle:

Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs

Session 3 FDA Audits and Findings

Nurse Aide Training Program Policies

Risk Assessment and Monitoring

I2S2 TRAINING Good Clinical Practice tips. Deirdre Thom Neonatal Nurse Coordinator

SOP MONITORING & OVERSIGHT OF RESEARCH ACTIVITY. Contact Jess Bisset, Research Operations Manager x20227

Chapter 48 - Bioresearch Monitoring

20 STEPS FROM STUDY IDEA INCEPTION TO PUBLISHING RESEARCH/ Evidence-Based Practice

Transcription:

Introduction to the United States Food and Drug Administration (FDA) and FDA Inspection Process VOICE 2011 MTN Annual Meeting March 27, 2011 Lisa Noguchi, MSN Donna Germuga, DAIDS, OCSO, RN, BSN

Objectives Understand why and how VOICE may be inspected by FDA Review proposed timeline for inspection preparation Get your feedback 2

FDA The FDA is an agency within the Department of Health and Human Services (DHHS) of the United States Government. United States Government Department of Health and Human Services (DHHS) FDA 3

Background US Food, Drug, and Cosmetic Act requires all new investigational drugs undergo clinical trials Role of US FDA Review clinical trial protocol Review sponsor marketing application Inspections of clinical trials sites, including participant charts, pharmacies, etc. Ensures safety of participants, consumers Verification that data are accurate and reliable Verify compliance with regulations and GCP guidance Verify control of study product 4

FDA Inspection Non-Clinical Laboratories Clinical Investigator Sites Principal Investigators FDA conducts on-site inspections of: Institutional Review Boards/Ethics Committees (IRB/EC) Sponsors Contract Research Organizations (CROs) 5

Why inspect VOICE? FDA agreed to use VOICE as second pivotal trial for the TFV gel licensure application Data will support marketing applications Oral drug supplementary marketing Gel initial application Large volume of participants 5,000 High enrollments at some sites International inspections are generally assigned when the studies covered are part of a marketing application to FDA and provide data critical to decision-making on product approval. FDA Compliance Program Guidance Manual 6

International Inspections 40-65% studies investigating FDA-regulated products are conducted outside US In 2008, 80% of marketing applications received by the FDA contained data from international clinical studies 78% of participants involved in studies supporting these applications enrolled at international sites 54% of the clinical sites conducting these studies were located outside the United States Challenges to FDA s Ability to Monitor and Inspect Foreign Clinical Trials, DHHS, June 2010 7

FDA Inspections of International Sites 1991-2008 8

Overview of the FDA Inspection Process Three Distinct Phases of an FDA Inspection: Phase 1 Before: Implement inspection preparation activities Phase 2 During: Perform roles/ responsibilities. Provide information to the inspector Phase 3 After: Review observations from the inspection and respond to FDA in writing 9

Which sites will be inspected? We don t yet know for certain Strong contenders High volume sites Sites with high number of HIV endpoints Sites identified as having potential issues with data quality or protocol compliance But, could be any number of VOICE sites! All sites should be prepared 10

Dealing with the unknowns Exact timing of inspections? Can estimate based on other trials Who will be inspected? Again, can formulate reasonable possibilities What will be inspected? Guidance will be given to sites on key areas of focus for preparation Example: documentation related to primary endpoint confirmation 11

FDA Inspection Preparation Timeline JUNE 2011 Enrollment completed OCT 2012 Data lock Feb 2013 Presentatio n of results FDA Inspection Prep Kick OFF OCSO monitoring trend analysis FDA Inspection Prep Training PART I PPD Special Assignments FDA Inspection Prep On Site Trainings PARTS II and III FDA Inspection Mar 2011 Sep 2011 Oct 2011 Oct 2011-12 Mar 2013 Summer 2013 12

What sites can do now to prepare? Develop a FDA Inspection SWAT TEAM (clinical, regulatory, pharmacy, and lab) Implement FDA prep checklist Use OCSO monitoring trend report and protocol deviation summary as tools for internal QA/QC Ensure timely submission of CRFs and response to queries to SDMC Ensure all monitoring report findings resolved Ensure Regulatory Binder is complete and orderly Re-evaluate and update CQMP 13

IPrEx 14

Summary If VOICE results show efficacy, there is high likelihood that sites will be inspected Who will be inspected and when remains to be determined Advance preparation is KEY to a successful FDA inspection and LESS STRESS! 15

Your Site Here 16